Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis
Journal of Thrombosis and Thrombolysis, Volume 19, No. 3, Year 2005
Notification
URL copied to clipboard!
Description
Background: Once- and twice-daily low-molecular-weight heparin administered in hospital have been shown to be effective and safe for treating deep-vein thrombosis. The aim of this study was to compare the efficacy and safety of deep-vein thrombosis treatment using once-daily subcutaneous enoxaparin in the outpatient setting with intravenous unfractionated heparin in hospital. Methods: This randomized, parallel-group, open-label study was conducted in 18 centers in 4 countries. In total, 298 patients with symptomatic deep-vein thrombosis who were eligible for home treatment were randomized to treatment with enoxaparin in the outpatient setting (1.5 mg/kg subcutaneously once-daily) or unfractionated heparin in hospital (5000 IU bolus and 1250 IU/hour intravenous infusion) for ≥ 5 days. Clinical endpoints were assessed during a 6-month follow-up period. Results: Among all patients treated with enoxaparin, there was a trend towards fewer recurrent deep-vein thromboses (1.3% vs. 5.4%; p = 0.060) and pulmonary emboli (1.3% vs. 4.1%; p = 0.17) compared with patients treated with unfractionated heparin. When considering a post-hoc combined endpoint of deep-vein thrombosis and pulmonary embolism, significantly fewer events occurred in the enoxaparin group than in the unfractionated-heparin group (2.7% vs. 8.8%; p = 0.026). The incidences of bleeding events and adverse events in the enoxaparin and unfractionated-heparin groups were similar. Conclusions: Once-daily subcutaneous enoxaparin in the outpatient setting is at least as effective and as well tolerated as in-hospital intravenous unfractionated heparin for treatment of deep-vein thrombosis. © Springer Science + Business Media, Inc. 2005.
Authors & Co-Authors
Chong, Beng Hock
Australia, Sydney
Prince of Wales Hospital
Australia, Kensington
Unsw Medicine
Australia, Sydney
St George Hospital
Brighton, Tim A.
Australia, Sydney
St George Hospital
Baker, Ross I.
Australia, Perth
The University of Western Australia
Thurlow, Peter
Australia, Melbourne
Austin Health
Lee, Choon H.
Australia, Penrith
Nepean Hospital
Salem, H.
Australia, Sydney
Box Hill Hospital
Gallo, J.
Australia, Liverpool
Liverpool Hospital
Clowes, C.
Australia, Bankstown
Bankstown-lidcombe Hospital
Hertzberg, Mark
Australia, Sydney
Westmead Hospital
Heaton, D.
New Zealand, Christchurch
Christchurch Hospital new Zealand
Leahy, Michael F.
Australia, Fremantle
Fremantle Hospital
Gibbs, Harry H.
Australia, Woolloongabba
Princess Alexandra Hospital
Ziaja, K.
Poland, Katowice
Clinic of General and Vascular Surgery
Karrim, A.
South Africa, Johannesburg
Helen Joseph Hospital
Louwrens, H.
South Africa, Cape Town
N1 City Hospital
Wright, N.
South Africa, Sandton
Sunninghill Hospital
Barry, R.
South Africa, Bloemfontein
Universitas Private Hospital
Jeffrey, P.
South Africa, Cape Town
Vincent Palotti Hospital
Kadwa, A.
South Africa, Durban
Chelmford Medical Centre No.2
Szoztek, M.
Poland, Warszawa
Clinic of Surgery and Thoracic Diseases
Michalak, J.
Poland, Luban
Clinic of Angiosurgery
Bester, Frederik C.J.
South Africa, Bloemfontein
Fichmed Medical Centre
Statistics
Citations: 54
Authors: 22
Affiliations: 23
Identifiers
Doi:
10.1007/s11239-005-1848-x
ISSN:
09295305
Research Areas
Health System And Policy
Study Design
Cohort Study